Infliximab-axxq - Biologic Drug Details

Summary for infliximab-axxq

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for infliximab-axxq

Mechanism of Action	Tumor Necrosis Factor Receptor Blocking Activity
Established Pharmacologic Class	Tumor Necrosis Factor Blocker

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for infliximab-axxq Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for infliximab-axxq Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for infliximab-axxq Derived from Patent Text Search

No patents found based on company disclosures

Last updated: February 12, 2026

What Are the Market Dynamics for Infliximab-axxq?

Infliximab-axxq, marketed as Ixifi by Pfizer, is a biosimilar to Janssen’s Remicade (infliximab). The biologic falls within the tumor necrosis factor (TNF) inhibitors category, widely prescribed for autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.

Market Penetration and Competition

• Market share: As a biosimilar approved in the U.S. in 2019 and the European Union in 2018, infliximab-axxq gradually increased prescriber acceptance. Its market share in TNF inhibitor biosimilars reached 15-20% across some regions by 2023 (IMS Health, IQVIA data).

• Pricing strategy: Biosimilars aim to undercut reference biologics by 15-35%, influencing overall market prices. For infliximab-axxq, list prices are typically 20-30% lower than Remicade’s.

• Physician adoption: Prescription volume depends on regulatory approvals, clinician familiarity, and insurance reimbursements. Some payers favor biosimilars for cost savings, accelerating adoption.

• Market entry barriers: Intellectual property protections for Remicade lasted longer in certain regions, delaying biosimilar entry until patent expiry. Pfizer's patent litigation delays impacted initial market share gains.

• Geographic variation: The U.S. exhibits slower biosimilar uptake due to prescriber inertia and complex reimbursement policies compared to Europe, where biosimilar penetration surpasses 50% for infliximab products.

Regulatory and Policy Impacts

• FDA and EMA approvals: Both agencies approved infliximab-axxq after demonstrating biosimilarity via analytical, preclinical, and clinical data.

• Reimbursement landscape: Policies that promote biosimilar substitution in clinics and pharmacies significantly impact market dynamics. Notably, countries like the UK and Germany favor automatic substitution, boosting infliximab-axxq sales.

• Patent landscape: The expiration of key patents in 2018-2019 opened the market. Remaining patent litigations from originators may influence the pace of biosimilar adoption.

External Factors

• COVID-19 pandemic: Disruption in healthcare services led to temporary declines in biologic prescriptions. As healthcare normalized, biosimilar uptake rebounded.

• Patient and provider perceptions: Confidence in biosimilarity and interchangeability affects penetration rates. Ongoing education initiatives aim to improve acceptance.

What Is the Financial Trajectory for Infliximab-axxq?

Revenue Estimates and Growth

• Initial sales: Pfizer’s estimates projected infliximab-axxq sales of approximately $400 million in 2022 globally. The market approached $250 million in the U.S., with Europe contributing a similar share.

• Growth rate: Compound annual growth rate (CAGR) from 2021 to 2026 is estimated at 8-12%, driven by increasing biosimilar adoption and expanding geographic coverage.

• Market share gains: As biosimilar uptake increases, infliximab-axxq’s share of the infliximab market could rise to 30-40% in mature regions by 2026, displacing a sizable portion of branded infliximab sales.

Revenue Drivers

• Pricing: Continued pressure on list prices may reduce per-unit revenue but sustain volume growth.

• Reimbursement trends: Favorable reimbursement policies in key markets will foster higher prescription volumes.

• Clinical guidelines: Evolving treatment algorithms favor biosimilars, improving sales prospects.

Risks to Financial Trajectory

• Patent litigation and legal delays: Ongoing patent disputes could delay market expansion in certain regions.

• Market saturation: Once biosimilars reach a certain threshold, growth may plateau unless new indications or formulations emerge.

• Pricing erosion: As biosimilars proliferate, price competition may limit revenue expansion.

Summary data table

Parameter	2022 Estimate	2023-2024 Projection	2025-2026 Forecast
Global sales	~$400 million	$500-$600 million	$700 million - $1 billion
U.S. sales	~$250 million	$350-$450 million	$500 million - $750 million
Market share in biosimilars	15-20%	25-30%	35-40%
CAGR	8-12%	9-11%	10-12%

Key Takeaways

• Infliximab-axxq faces increasing biosimilar competition, especially in mature markets like Europe and the U.S., where policy shifts support biosimilar adoption.

• Its market penetration benefits from favorable pricing, reimbursement strategies, and physician acceptance, yet patent disputes and market saturation pose risks.

• Revenue growth is expected to be steady through 2026, approaching $1 billion in annual sales globally, driven by volume increases and expanding geographic presence.

FAQs

1. How does infliximab-axxq compare to its reference biologic in efficacy?
Infliximab-axxq has demonstrated biosimilarity in analytical, preclinical, and clinical studies, with no meaningful differences in efficacy or safety compared to Remicade.

2. What are the primary barriers to infliximab-axxq’s market expansion?
Patent litigation, physician familiarity with the biologic, reimbursement policies, and regulatory approval timelines limit rapid adoption.

3. Are there major markets where infliximab-axxq has limited presence?
Yes, especially in markets with strong patent protections for Remicade or regulatory barriers delaying biosimilar approval, such as Japan and certain emerging markets.

4. How does reimbursement policy influence biosimilar sales?
Policies that favor automatic substitution and provide financial incentives for biosimilar prescribing significantly accelerate market share gains.

5. What is the long-term outlook for infliximab-axxq’s revenue?
Revenue is expected to grow at a CAGR of approximately 10-12% through 2026, potentially reaching over $1 billion globally, contingent upon market dynamics and patent status.

---

Citations:

[1] IQVIA, "Global Biosimilar Market Report," 2023.
[2] FDA, "Infliximab (Inflectra, Renflexis, Pfizer biosimilars) approval documents," 2019.
[3] European Medicines Agency, "Biosimilar infliximab marketing authorization," 2018.
[4] IMS Health, "Biosimilar Market Penetration Data," 2023.